nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, liver fibrosis


The review is devoted to the problem of diagnosing one of the most common pathologies of the modern world – non-alcoholic fatty liver disease (NAFLD). Data from experimental and clinical studies on the importance of various instrumental and biochemical methods of non-invasive diagnosis ofnon-alcoholic steatohepatitis (NASH) and liver fibrosis (LF) are presented. New non-invasive diagnostic methods of NASH and LF are considered.


Cobbina E., Akhlaghi F. (2017). Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017 May; 49(2):197-211. doi: 10.1080/03602532.2017.1293683.

Asrani S.K, Devarbhavi H., Eaton J., et al. (2019). Burden of liver diseases in the world. J Hepatol. 2019 Jan;70(1):151-171. doi: 10.1016/j.jhep.2018.09.014.

Papatheodoridi M., Cholongitas E. (2018). Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Curr Pharm Des. 2018; 24(38):4574-4586. doi:10.2174/1381612825666190117102111.

Younossi Z., Anstee Q.M., Marietti M., et al. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109.

Sanyal A.J., Brunt E.M., Kleiner D.E., et al. (2011). Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011 Jul; 54(1):344-53.doi: 10.1002/hep.24376.

Bravo A.A., Sheth S.G., Chopra S.N. (2001). Liver biopsy. Engl J Med. 2001 Feb 15; 344(7):495-500.doi: 10.1056/NEJM200102153440706.

Rockey D.C., Caldwell S.H., Goodman Z.D., et al. (2009). Liver biopsy. Hepatology. 2009; 49:1017–1044.doi: 10.1002/hep.22742.

West J., Timothy R.C. (2010). Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies Gastroenterology, 2010. Volume 139, Issue 4, 1230 – 1237. doi:10.1053/j.gastro.2010.06.015.

Vernuccio F., Michael D.Rosenberg, Mathias Meyer et al. (2019). Negative Biopsy of Focal Hepatic Lesions: Decision Tree Model for Patient Management. American Journal of Roentgenology 2019 212:3, 677-685.doi: 10.2214/AJR.18.20268.

Zhu J.Z., Hollis-Hansen K., Wan X.Y., et al. (2016). Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. World J Gastroenterol. 2016 Sep 28;22(36):8226-33. doi:10.3748/wjg.v22.i36.8226.

Saadeh S., Younossi Z.M., Remer E.M., et al. (2002). The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745–750.doi:10.1053/gast.2002.35354.

European Association for the Study of the Liver, and European Association for the Study of Diabetes (EASD). "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease." Obesity facts 9.2 (2016): 65-90.doi: 10.1159/000443344.

Lee S.S., Park S.H., Kim H.J., et al. (2010). Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010;52:579–85. doi: 10.1016/j.jhep.2010.01.008.

Kodama Y., Ng C.S., Wu T.T., et al. (2007). Comparison of CT methods for determining the fat content of the liver. 2007 May; 188(5):1307-12. doi: 10.2214/AJR.06.0992.

Jennison E., Patel J., Scorletti E., et al. (2019). Diagnosis and management of non-alcoholic fatty liver disease/ Postgraduate Medical Journal 2019;95:314-322. doi:10.1136/postgradmedj-2018-136316

Longo R., Pollesello P., Ricci C., et al. (1995). Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281–5.doi: 10.1002/jmri.1880050311.

Zhong L., Chen J.J., Chen J., Li L., et al. (2009). Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy. J Dig Dis 2009; 10: 315–20.doi: 10.1111/j.1751-2980.2009.00402x.

Chen J., Talwalkar J.A., Yin M., Glaser K.J., et al. (2011). Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011 Jun; 259(3):749-56.doi: 10.1148/radiol.11101942

Sandrin L., Fourquet B., Hasquenoph J.M., et al. (2003). Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29: 17051713.doi: 10.1016/j.ultrasmedbio.2003.07.001.

Newsome P.N., Sasso M., Deeks J.J., et al. (2020). FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8.

Eddowes P.J., Sasso M., Allison M., Tsochatzis E., et al. (2019). Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042.

de Lédinghen V., Vergniol J. (2008). Transient elastography (FibroScan). Gastroenterol Clin Biol. 2008 Sep; 32(6 Suppl 1):58-67.doi: 10.1016/S0399-8320(08)73994-0.

Pang J.X., Zimmer S. Niu S., Crotty P., et al. (2014). Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One. 2014; 9(4):e95776.doi: 10.1371/journal.pone.0095776

Bedogni G., Bellentani S., Miglioli L., Masutti F., et al. (2006). The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2; 6():33.doi: 10.1186/1471-230X-6-33

Kabisch S., Bäther S., Dambeck U., Kemper M., Gerbracht C., Honsek C., Sachno A., Pfeiffer A.F.H. Liver Fat Scores Moderately Reflect Interventional Changes in Liver Fat Content by a Low-Fat Diet but Not by a Low-Carb Diet. Nutrients. 2018 Jan 31;10(2):157.doi:10.3390/nu10020157.

Jun H.K., Jin S.M., Seok J. B. et al. (2020). Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study, Cardiovascular Diabetology, 2020 May 2;19(1):51. doi:10.1186/s12933-020-01025-4.

Lee J.H., Kim D., Kim H.J., Lee C.H., et al. (2020). Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010 Jul; 42(7):503-8.doi:10.1016/j.dld.2009.08.002

Karmen A., Wroblewski F., Ladue J.S. (1995). Transaminase activity in human blood. J Clin Invest. 1955 Jan;34(1):126-31. doi: 10.1172/JCI103055.

Kwo P.Y., Cohen S.M., Lim J.K. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35.doi:10.1038/ajg.2016.517.

Oh M.K., Winn J., Poordad F. (2008). Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008 Sep 1;28(5):503-22.doi:10.1111/j.1365-2036.2008.03752.

Vroon DH, Israili Z. (1990). Alkaline Phosphatase and Gamma Glutamyltransferase. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworths; 1990. Chapter 100. PMID: 21250047.

Dufour D.R., Lott J.A., Nolte F.S. et al. (2020). Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050–2068.doi: 10.1093/clinchem/46.12.2050

Kunutsor S.K., Kieneker L.M., Burgess S., Bakker S.J.L., Dullaart R.P.F. Circulating total bilirubin and future risk of hypertension in the general population: the prevention of renal and vascular end-stage disease (PREVEND) prospective study and a mendelian randomization approach. J Am Heart Assoc. doi: 10.1161/JAHA.117.006503

Chang Y., Ryu S., Zhang Y., et al. (2012). Cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers, Guallar E PLoS One. 2012; 7(5):e37241.doi: 10.1371/journal.pone.0037241

Yang M.H., Sung J., Gwak G.Y. (2016). The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016 Mar-Apr;10(2):289-98. doi: 10.1016/j.jacl.2015.11.017.

Fadaei R., Poustchi H., Meshkani R., et al. (2018). Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep. 2018 Aug 3;8(1):11691.doi: 10.1038/s41598-018-29639-5.

Quaye I.K. (2008). Haptoglobin, inflammation and disease. Transactions of the Royal Society of Tropical Medicine and Hygiene. 102. 735-42. 10.1016/j.trstmh.2008.04.010.doi:10.1016/j.trstmh.2008.04.010.

Chwist A., Hartleb M., Lekstan A., et al. (2014). A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study. Pol Arch Med Wewn. 2014; 124(12):704-12.doi: 10.20452/pamw.2558.

Copyright for articles published in the journal is regulated by the License Agreement for the use of a scientific article in the journal, which is concluded between the author of the article (Licensor) and Kharkov National Medical University (Licensee, publisher of the journal "Inter Collegas"). The licensor grants to the Licensee a non-exclusive non-exclusive license for the use of the article (a license that does not exclude the use of the article by the Licensor and the issuance of licenses to others for use of this article) on the terms and for the period specified in the contract. The licensor (the author of the article) grants the Licensee the right to reproduce the article (publication in the journal "Inter Collegas", publication, duplication, duplication or other reproduction of the article without limiting the circulation of copies, each copy of the article must contain the name of the Licensor; Of general information, including the publication of the article in full or in part on the Internet on the journal page, the right to use the metadata of the article (titles, full names of authors, annotations, bibliography eskih materials) through the dissemination and communication to the public, processing and systematization, as well as inclusion in various databases and in-formational system).

The licensor grants the licensee the right to transfer, store and process his personal data (full name, scientific degree, academic title, place of work and position, contact information of the authors) with the purpose of including them in the database in accordance with the Law of Ukraine No. 2297 - VI "on protection of personal data" from 01.06.2010.

Personal data and metadata of the article are provided for their storage and processing in various databases and information systems, including them in analytical and statistical reporting, creating sound relationships between the objects of works of science, literature and art with personal data, etc. on unlimited territory. The licensee has the right to transfer the specified data for processing and storage to third parties provided that such a fact is notified with the provision of information about the third party (name and address) to the Licensor.